Quick Answer
Amphastar Pharmaceuticals, Inc. reported Gross Profit of $356.06 million for the year ending 2025.
- Amphastar Pharmaceuticals, Inc. showed a decrease of -4.8% in Gross Profit from 2024 to 2025.
- This data is from Amphastar Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2013: $27.49 million | Q3 2013: $20.28 million | Q4 2013: $19.63 million | Q1 2014: $12.51 million | Q2 2014: $15.00 million | Q3 2014: $11.79 million | Q4 2014: $11.96 million | Q1 2015: $13.28 million | Q2 2015: $13.32 million | Q3 2015: $17.58 million | Q4 2015: $33.17 million | Q1 2016: $24.90 million | Q2 2016: $31.71 million | Q3 2016: $27.61 million | Q4 2016: $19.96 million | Q1 2017: $22.81 million | Q2 2017: $26.66 million | Q3 2017: $20.55 million | Q4 2017: $20.49 million | Q1 2018: $16.97 million | Q2 2018: $26.06 million | Q3 2018: $29.26 million | Q4 2018: $34.69 million | Q1 2019: $30.90 million | Q2 2019: $32.39 million | Q3 2019: $35.25 million | Q4 2019: $33.38 million | Q1 2020: $36.82 million | Q2 2020: $33.18 million | Q3 2020: $36.51 million | Q1 2021: $44.95 million | Q2 2021: $47.38 million | Q3 2021: $51.18 million | Q1 2022: $55.83 million | Q2 2022: $63.36 million | Q3 2022: $58.51 million | Q1 2023: $73.84 million | Q2 2023: $72.74 million | Q3 2023: $108.40 million | Q1 2024: $90.10 million | Q2 2024: $95.17 million | Q3 2024: $101.94 million | Q1 2025: $85.25 million | Q2 2025: $86.49 million | Q3 2025: $98.65 million.
- Over the full 14 years of available data (2012 to 2025), Amphastar Pharmaceuticals, Inc.'s Gross Profit has grown by 294.3%.
- Historical annual values: Fiscal year 2025: $356.06 million | Fiscal year 2024: $373.86 million | Fiscal year 2023: $351.12 million | Fiscal year 2022: $248.86 million | Fiscal year 2021: $199.74 million | Fiscal year 2020: $143.34 million | Fiscal year 2019: $131.92 million | Fiscal year 2018: $106.99 million | Fiscal year 2017: $90.51 million | Fiscal year 2016: $104.20 million | Fiscal year 2015: $77.35 million | Fiscal year 2014: $51.26 million | Fiscal year 2013: $86.96 million | Fiscal year 2012: $90.30 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: